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Background: Clinical trials remain the cornerstone of improving outcomes for HIV-infected individuals with
cryptococcal meningitis. Community engagement aims at involving participants and their advocates as partners in
research rather than merely trial subjects. Community engagement can help to build trust in communities where
these trials are conducted and ensure lasting mutually beneficial relationships between researchers and the
community. Similarly, different studies have reported the positive effects of social support on patient’s outcomes.
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food, wheel chairs, imaging studies, adult diapers, and other extra investigations or drugs that were not covered by
the study budget or protocol. The benefits of this community engagement and social support were assessed
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Results: We screened 1739 HIV-infected adults and enrolled 934 with cryptococcal meningitis into the COAT and
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in 2010 to less than 1% in 2017. In our opinion, community engagement and social support played an important
role in improving: drug adherence, acceptance of lumbar punctures, data completeness, rate of screening/referrals,
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Plain English summary
Involving patients and the public in healthcare and sci-
entific research is increasingly becoming more import-
ant. It aims at involving patients’ community and their
advocates as partners in scientific research rather than
merely study subjects. Similarly, social support given to
patients has previously been shown to have positive ef-
fects on patient’s treatment outcomes. In this study we
aimed to highlight the benefits of community engage-
ment and social support in two clinical studies managing
patients co-infected with HIV and cryptococcal meningi-
tis. We engaged the patients and their caregivers using
home visits, health talks, posters, music and drama. In
addition, we provided social support through study staff
individually contributing to provide funds for partici-
pants’ food, wheel chairs, imaging studies, adult diapers,
and other extra tests or drugs that were not covered by
the study budget. The benefits of this community en-
gagement and social support were assessed. Lumbar
puncture refusal rates decreased from 31% in 2010 to
less than 1% in 2017. In our opinion, community en-
gagement and social support played an important role in
improving: drug adherence, acceptance of lumbar punc-
tures, data completeness, rate of screening/referrals, re-
duction of missed visits, and loss to follow-up. We
therefore conclude by saying that community engage-
ment and social support are very important aspects of
clinical and scientific research and should be incorpo-
rated into the initial clinical study design and conduct.
Background
Uganda is found in sub-Saharan Africa (SSA) where the
prevalence of human immunodeficiency virus (HIV) and
HIV-related opportunist infections is high [1, 2]. How-
ever, there is significant progress in the prevention and
treatment of HIV in SSA mainly due to the massive roll
out of antiretroviral treatment (ART) and recommenda-
tion to treat all HIV positive patients regardless of CD4
T-cell count [3]. Cryptococcal meningitis accounts for
15–25% of all HIV-related deaths [4–7]. An estimated
4000 HIV infected Ugandans develop Cryptococcus in-
fection annually in the absence of screening and pre-
emptive treatment for asymptomatic cryptococcal infec-
tion, and the estimated overall annual HIV-related
cryptococcal mortality in Uganda is nearly 2500 deaths
per year [7]. However, there remains a low index of clin-
ical suspicion for all fungal infections in Uganda [8, 9].
Clinical trials provide a platform for improving out-
comes for HIV-infected individuals with cryptococcal
meningitis [10–14].
Community engagement in scientific research is de-
fined broadly as the many ways in which the activities
and benefits of scientific research can be shared with the
community [15]. It can help build trust in communities
where scientific research is conducted, improve commu-
nity support for clinical research and ensure lasting mu-
tually beneficial relationships between researchers and
the community. Community engagement in clinical re-
search should be a two-way process involving inter-
action, exchange and listening, with the aim of mutual
benefit. Ideally, community engagement should begin as
early in the biomedical research or clinical trial process
as possible [16–18]. However, it is never too early or too
late to involve the patients and participant community
in a clinical trial.
Social support is a multifaceted experience that in-
volves voluntary associations and is comprised of formal
and informal relationships with others [19]. In sub-
Saharan Africa, the majority of clinical trials are con-
ducted in infectious diseases [20], which are the com-
monest causes of morbidity requiring hospitalization. A
large proportion of inpatients enrolled in these trials
present late with advanced disease. Thus, study partici-
pants are usually very ill and need social support to cope
with the burden of disease, pill burden and multiple
study procedures, which may be invasive in nature. This
kind of social support can also be extended to the care-
givers who are usually traumatised psychologically by
the suffering of the patients. A few studies have reported
the positive effects of social support on disease prognosis
[21, 22] and similarly, low social support has been asso-
ciated with worse treatment outcomes in different pa-
tient populations [19, 23].
In this article, we retrospectively describe the impact
and benefits we have observed by actively engaging the
patients’ and health workers’ communities together with
providing extra social support during two prospective
multi-site randomized clinical trials, which enrolled pa-
tients co-infected with HIV and cryptococcal meningitis
in sub-Saharan Africa.
Methods
Our Meningitis Clinical Research Team based at the In-
fectious Diseases Institute (IDI) Kampala Uganda, is dedi-
cated to reducing advanced HIV-associated mortality by
improving the diagnosis and management of common op-
portunistic infections, including meningitis. From October
2010 to July 2017, we conducted two large clinical trials
during which we participated in community engagement
and provided social support to study participants and their
caregivers outside the usual study protocols. The Crypto-
coccal Optimal ART Timing (COAT) trial (ClinicalTrials.-
gov number, NCT01075152.), was conducted between
2010 and 2012. This randomised multi-centre clinical trial
conducted in Uganda at Mulago National Referral Hos-
pital, Mbarara regional referral hospital and Cape Town in
South Africa evaluated the optimal timing of antiretroviral
therapy (ART) initiation among patients with cryptococcal
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meningitis [11]. The results from this trial led to the
current World Health Organization (WHO) recommen-
dation that ART-naïve patients with cryptococcal menin-
gitis should initiate ART 4–6 weeks following diagnosis
and treatment of cryptococcal meningitis [24]. The second
trial was the Adjunctive Sertraline for the Treatment of
HIV-Associated Cryptococcal Meningitis (ASTRO-CM)
study (ClinicalTrials.gov, number NCT01802385), a ran-
domized multi-centre clinical trial conducted in Uganda
at Mulago National Referral Hospital and Mbarara Re-
gional Referral hospital between 2013 and 2017 [14]. This
study evaluated the efficacy of adjunctive Sertraline as an
antifungal drug for cryptococcal meningitis.
During both trials, we consented and screened 1739
HIV infected patients for meningitis and enrolled 934
patients. Herein, we discuss the benefits observed by ac-
tively engaging the patients, health workers and commu-
nities complemented by extra social support for trial
participants. We followed the Guidance for Reporting
Involvement of Patients and the Public (GRIPP2) check-
list [25] (Additional file 1).
Results and discussion
Community engagement and its benefits
In these clinical trials, we were initially encouraged to
engage the surrounding communities due to the high
rate of refusal for lumbar punctures (25%) [26, 27], des-
pite their diagnostic and therapeutic importance. Both
clinical trials involved regular lumbar punctures per-
formed to diagnose cryptococcal meningitis; performed
at days 0,3,7,10, and 14 of treatment and as clinically in-
dicated. In many African settings, there are many myths
surrounding lumbar punctures. The majority of patients
and/or their caregivers believed that lumbar punctures
increased one’s chances of dying prematurely. We regis-
tered a 31% (n = 177) refusal rate in our first cohort [11]
and this delayed diagnosis and prolonged the screening
consenting process.
In an effort to reduce on the refusal rate for lumbar
punctures, we initially made posters about lumbar punc-
tures in English with additional translation into the local
language (Luganda) (Fig. 1). The posters had a cartoon
depiction of the lumbar puncture procedure, details on
its importance, and indications for the procedure. These
were placed on the infectious diseases and neurology
wards. Other copies were given as handouts to the
intern doctors rotating on these wards. This increased
awareness about lumbar punctures and our research
study among this community of health care providers
and potential participants.
We then engaged the health workers (doctors, nurses
and interns) about the clinical study we were conducting
to raise awareness and get more referrals for study par-
ticipants. In addition, we went out and sensitized more
health care workers in other health centers and hospitals
about cryptococcal meningitis and the clinical trial that
was underway to encourage referrals. We conducted
training focused on cryptococcal antigen (CrAg) screen-
ing in these peripheral centers. This engagement in-
creased the referrals we received from peripheral health
centers that could not perform lumbar punctures from
zero (0) to 17 patients per month.
On a weekly basis, one of the nurses would gather all
available caregivers for study participants on the ward and
conduct health education. These talks emphasized the care
of inpatients including patients’ hygiene, nutrition, ambula-
tion, proper feeding, medication, and infection control dur-
ing hospitalization and post discharge [10]. The caregivers
were also reminded about the study procedures and their
rights as regards the study. It is on the same platform that
the myths about lumbar punctures were discussed and dis-
pelled. We encouraged them to freely ask any questions
about the study, myths and patient care. This helped to im-
prove patients’ hygiene, nutrition and infection control dur-
ing admission. Those caregivers that had understood what
had been discussed were co-opted to share with other po-
tential participants their own experience. These efforts also
helped to increase the acceptance rate for lumbar punctures
and recruitment rate.
In relation to the above, we also selected leaders among
the patients’ caregivers to encourage others on drug ad-
herence by reminding them to take their drugs on time.
The leaders also helped patients who did not have care-
givers to pick their drug prescriptions from the pharmacy
and food from the kitchen staff. This effort helped to re-
tain patients in care and improved adherence and treat-
ment outcomes without missing any doses.
When participants missed several scheduled clinic
visits (at least 3), and were uncontactable by phone, the
team conducted a home visit for those who consented to
home visits. During these home visits, we engaged the
patient’s family members and available neighbors and
discussed issues related to HIV stigma, myths, holistic
care, study procedures and any other concerns the par-
ticipant had about the study while emphasizing the need
to keep all clinic appointments and adhere to prescribed
medications. In addition, during these visits, we collected
more contacts from other individuals whom the partici-
pant recommended, who could easily be contacted in
case the participant could not be reached.
We also created a short movie about the importance
of lumbar punctures in diagnosing meningitis (https://
www.youtube.com/watch?v=222eM9s7xq0). This 20-min
film was shown to patients, caregivers and health
workers in order to increase awareness and decrease
stigma around lumbar punctures. It so far has 96 views
on YouTube. However, we estimate that more than 1000
people viewed the video in the places/clinics where it
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Fig. 1 Poster for lumbar puncture procedure. a) English version, b) Luganda version
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was screened. More recently, we conducted a commu-
nity engagement event during which we educated the
community about meningitis through music and drama.
The music and drama events were aimed at engaging
the hard to reach young adults who may be discon-
nected from HIV care in order to raise awareness about
HIV, meningitis, the safety of lumbar punctures and on-
going meningitis clinical trials. The series of community
engagement events we held were aimed at giving the ac-
tive clinical research participants and those that success-
fully completed the trials a voice in sharing their
experiences of clinical research and messages of hope
around advanced HIV disease with the community, dis-
pelling myths and stigma around HIV, raising awareness
about the complications of advanced HIV disease and
local ongoing clinical research and recent scientific ad-
vances. We also provided our phone contacts to the pa-
tients and so they would call us for free consultation
even after the end of the trial.
Social support and its benefits
For each study participant, we provided transport reim-
bursement for each scheduled outpatient clinic and sick
visit. The amount was guided by ethics committee ap-
proval, thus this was not unique to our trial. However,
in our study, most of our patients were very sick and re-
quired a number of caregivers to escort them for the
clinic visit. This meant that we had to provide transport
reimbursement for the patient and all accompanying
caregivers. This would encourage the caregivers to
promptly bring the patients for their clinic visits without
fail. In addition, the majority of patients resided in rural
areas far away from the clinic. This meant that the trans-
port reimbursement tended to be higher than the pre-
determined amount. Since we contacted the participants
the day before each clinic visit, some informed us that
they did not have any money to transport them for their
return clinic visit. In such cases, we disbursed the money
to them via “a mobile money” platform to ensure that
appointments were kept.
Since the majority of participants were referred from
rural areas, some had significant financial challenges and
were unable to afford meals yet they had to take mul-
tiple medications including, but not limited to ART, an-
tifungals, painkillers and multivitamins. In such cases,
we provided financial support for food that came from a
pool of donated money from study staff. This would help
to avoid missing medications and improve adherence
despite the high pill burden. Similarly, we partially sup-
ported participants to find accommodation to ensure
that clinic visits were not missed when due. After the
study period, we facilitated the referral of some partici-
pants to clinics that were nearest to where they were re-
locating. Occasionally, study staff collected to a small
‘social responsibility fund’ to contribute to food, wheel
chairs, imaging studies, adult diapers, and other extra in-
vestigations or drugs that were not covered by the study
budget while also helping some participants to start up
small income generating businesses to take care of their
own food, rent and other basic needs. In addition, study
staff would donate clothes and shoes to the very needy pa-
tients. This encouraged the participants to remain in the
study while building close relationships with study staff.
There was a proportion of study participants who had
no caregivers at all. These are usually brought to hos-
pital by either relatives, neighbors or “good Samaritans”
and then abandoned. Since they are usually very sick
and disoriented, we hired social workers to take care of
such patients. In the Ugandan context, a medical social
worker is one that is responsible for the emotional, so-
cial and economic welfare of patients admitted in the
hospital and those brought to the hospital without close
relatives including abandoned children. In cooperation
and participation with health workers, the social worker
investigates the family situations traumas and worries of
patients who appear helpless and those unable to meet
their health and medical care costs. They follow up com-
plicated cases and give necessary advice to the health
workers, Hospital Administration and the patients or
their relatives. In our case, the social workers helped to
pick their drug prescriptions from the pharmacy and
food from the kitchen staff. They also cleaned up the pa-
tients and their beddings, and fed them as needed. They
ensured that all medications were taken on time. How-
ever, in the absence of the social workers, all this would
be done by the study nurses. This helped such patients
to adhere to study medication, avoid nosocomial infec-
tions and eventually getting lost to follow-up.
A few of the study participants did not have mobile
phones yet we needed to contact them for reminders
about their clinic visits. These were mostly those without
caregivers whose contacts would be taken as an alterna-
tive. In such cases, we bought basic mobile phones for
the patient so as to stay in touch for follow up. These
phones would also help us obtain verbal autopsies for
participants who died at home. We would also send mo-
bile money on these phones in case the patient needed
transport to bring them for the clinic visit. Calls were
made more often to these patients without caregivers to
ensure adherence to all drugs.
Home visits were recommended when a patient
missed two clinic visits and could not be reached by
phone. As discussed above, families of the patients were
engaged during home visits and discussed issues pertain-
ing to care of participants and the relevance of attending
clinic visits. The visiting counselor probed the partici-
pant to understand why visits were missed and found
ways of troubleshooting to avoid them in future. In
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addition, during these visits, we collected more contacts
from other individuals/next-of-kin who could easily be
contacted in case the participant could not be reached.
Some funders of clinical trials have limitations to how
much extra support you can give a participant beyond
the routine clinical and lab investigations directly con-
nected to the trial outcome. However, it should be noted
that the social support provided was not used as an un-
ethical means of persuading the participants to accept
preceding medical or study procedures. Besides it was
entirely voluntary on the side of the health workers and
contributions were made after participants had been en-
rolled in the trials.
Limitations of the study
The benefits presented in this paper are based on our
experiences in Kampala during two longitudinal mul-
tisite HIV trials. The experiences may not be applic-
able in all resource-limited settings due to variations
in socio-economic factors. Many of the observations
made in this article are qualitative observations that
lack quantitative outcome data. The reason for this
paper is to highlight the importance of community
engagement and social support to clinical trials, but
trials specifically designed to evaluate the outcomes
are lacking. These trials are needed to help inform fu-
ture trial design about the most impactful and cost-
effective interventions.
Conclusion
Community engagement has increasingly become an im-
portant aspect of scientific research and is currently en-
couraged by many funders as part of research grant
applications. It creates opportunities for dialogue and
encourages the research participants to fully engage in
the study when they understand it well. Social support
as described in this paper is an aspect that has not been
applied in many clinical studies and therefore the extent
of its benefits is unclear. However, with these two strat-
egies, we observed many benefits that we believe con-
tributed to the minimal loss to follow up during these
trials. They helped us to improve adherence, acceptance
of lumbar punctures (from 31% to less than 1%), data
completeness, rate of screening and referrals. In
addition, we managed to minimize missed visits and at-
trition of participants.
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